Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Xspray, Press Conference

By Inderes8/20/2026, 7:00 AM
Xspray Pharma

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Blake Leach
00:00 - 24:51

Good morning, investors and media, and thank you for the strong participation this morning. As mentioned, I'm Blake Leach, CEO of Xspray, and I thank Jacob and Sofia for helping to moderate today's call. Today I am here to provide color to the CRL announced yesterday and help to answer questions you may have. Before I get into that, I just want to pause and step back. 20 years ago this summer, Sprycel was approved in America. Sprycel helped to turn a once life-changing condition into a manageable, near-normal life expectancy. Dasatinib remains today a key treatment option in leukemia. Last year alone, revenues of Dasatinib were about 1.9 billion USD. And yet the medical need for improved dasatinib after 20 years is clear. Dasatinib has demonstrated bioequivalence at a 30% lower dose and is designed to enable concomitant use with acid-reducing medicines. This is an important benefit to patients, nurses, and physicians. Our view of the dasatinib landscape is unchanged. The CRL does not change our view of the potential of Dasanib. Certainly not of the high-net platform technology, nor the commercial opportunity ahead. The remaining issue is still centered on the regulatory status at Near Pharma, which has been known to the market and is ultimately in the FDA's hands. But this is not a new fundamental problem. We have previously communicated that the approval of Dasynoc remains dependent on the resolution of the outstanding regulatory requirements related to Neopharm, and that the timing of FDA processes cannot be controlled or guaranteed by Xspray. Now, in the Q2 report a couple of weeks ago, I outlined that this could be time-sensitive and tight. Ahead of the August 25th date, we stated that the FDA could issue a CRL because the inspection of the facility had not yet been completed, while a Nyr Pharma clearance during the autumn would likely be consistent with launch readiness. The additional batch data request that was received within the CRL is absolutely manageable in substance. We already believe that the submitted quality package is strong and within the FDA's expectations. What the FDA is asking for now is more commercial-scale evidence, which just means producing and documenting additional batches that were, in any case, part of our launch preparation. I also want to highlight what was not in the CRL; there were no questions related to bioavailability, bioequivalence, stability, or the risk of medication errors, as was evident in previous calls, which indicates that we have now resolved these lingering issues. So this is not a product quality problem, and it does not change at all our clinical or commercial rationale. The benefits of Dasatinib are very strong, both in bioequivalence and with acid-reducing medicines. Today we remain focused on the bigger vision, bringing improved treatments to patients while preparing for a rapid launch. Once the remaining regulatory requirements are resolved, the batch work will be accelerated so that we can ensure that we are able to resubmit in 2026. We are ready to commercialize once we have clearance, and we have EverSana already at our side and ready to start our US commercial operations and organization once that occurs. So thank you. Those are my opening remarks. And Sofia and Jacob, I would like to open up to questions, please. If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Philip Einarson from Redeye. Please go ahead. Hi, everybody. Thank you for taking my questions. I want to start off on the batch data. And maybe if you could just clarify a little bit further, what sort of data is it that has been requested and if it will require several batches? Thank you. What is requested is commercial-scale consecutive batch data. Now, as we are preparing for commercial launch, this was obviously within our anticipated development plans this fall. The request is not surprising for us. And whilst we do have plans to provide these commercial batches, we will now evaluate how we can accelerate that together with our partner to ensure that we can develop the resubmission as quickly as possible. Right, so a follow-up to that would be, do you have any sort of estimate of how long that process would be from where we stand right now to produce these batches that would be required. At the current moment. We are working with our partners at NRx Pharmaceuticals; I can assure you and the market that we have an expedited time frame already under development, and we will aim to complete this as soon as possible in the coming weeks. Okay, the next one then, maybe if you could clarify the issues that have been resolved in this CRL compared to the last. To be very clear, one of the major questions that was provided in a previous CRL related to the risk of medication error that has been substantially addressed through our resubmission in February, and it no longer features in the discussion with the FDA as outlined in the CRL. Okay, good. And so the last one for me: with this extended timeline, should we expect a down-prioritization of Excess-008 and A025 to further reserve the cash runway? Any comment on that? Yes, thank you. It is a good point indeed. Yes, I think our resources will be focused to ensure that we realize the launch of our two products that are currently undergoing FDA review, those being the designated assets. And at the same time, we need to balance that with our commercial readiness, and we will continue to be vigilant in our capital expenditure to focus on driving forward the portfolio and ensuring that we are commercially ready so that we are not delayed upon commercial launch. Okay. Thank you all from me. Thank you. As a reminder, if you wish to ask a question, please dial pound key five on your telephone keypad. There are no more phone questions at this time, so I hand the conference back to the speakers for any written questions or closing comments. Thank you, Sophia, this is Jacob. I have the written questions in front of me, and there are a number of questions, some of which are quite long and cover the same topics that we already touched upon. So I will try to do my best to extract the parts that we did not already cover. Thomas Plot has posted a number of questions concerning the batch manufacturer. And just to clarify, one of the questions is: did you already manufacture batches or is this something that we need to do from scratch with Neuraxpharm? We are, in fact, Jacob, and thank you. We have produced multiple batches through the course of the development of Daznok. And in fact, we also, as part of our resubmission in February, appended five batches that were developed post the implementation of our corrective actions. So the development of new batches or the request for consecutive commercial-scale batches, which is really what the FDA is asking for, is within our operating plan already, and we will continue to accelerate and ensure that we develop these as we move forward quickly. And there is also a detailed question here about the timing that might have some value, regarding whether commercial scale batches were manufactured after the CAPA activities were completed as part of the remediation plan before the CRL was received. No, the answer to that is no, they were not. No, they have not been. That is why we have that activity already planned for within our commercial scale-up activities. Moving on to Near Pharma. Thomas Clot again has a question whether we anticipate that the FDA will need to conduct a new inspection. Or is it possible that they could resolve it based on the documentation and commercial batch data? He does not mention the previous inspection, but I suppose that is also included in the alternatives. Can you shed some light on what we know about that? At this point, we are anticipating a response and a decision from the FDA as it relates to the OAI status at Near Pharma. That decision is within the FDA's purview to make, as you indicated, Efor completed an inspection earlier this year in May, in fact, with an outcome that was positive, as our partners at Benton Group and Near Pharma have communicated to us and I have communicated previously to the market. So at this point, we are waiting for the FDA's decision on whether or not they require an additional inspection and or if they would rely on the information that potentially would be provided from a mutual recognition route. But at this point, I do not want to speculate on timing or, certainly, the FDA's decision. Yes, I understand, and timing is, of course, an issue that concerns many of the people asking questions. There is also one wanting to specify, assuming the required commercial batches can be manufactured without issues, what is your current realistic timeline for submitting the response to the FDA? What do we say about that? What can we say about that? Well, I can certainly say that we expect to resolve this batch data question and work stream within the coming weeks, and that we anticipate resubmitting in 2026. Yes, the same person also observed that the previous CRL for Nul also requested additional information from commercial scale manufacturing. And how do those two relate to each other? I think the question is to what extent can those be coordinated or can they even be done simultaneously. Done simultaneously. It is important to note that we have the same factory that underpins both development programs. Near Pharma is our third-party contractor that is helping us to develop both the key opportunity in front of us for Daznock. The questions that were raised in the CRL relate to the Dasanoc dossier and are not linked to PKI. As you may recall, Nucala has had different questions that are being addressed at this moment. So we again will be focusing our manufacturing activity in the coming weeks to satisfy our needs for commercial scale manufacturing of both products. And thank you. I think the questions that I have in front of me now are on the same topics. So, let me have just a brief moment to see the time. Yes, we do have some questions from several people about financing. Is the current cash position sufficient to reach approval and launch? And more specifically. There is a person asking. Whether we should anticipate a new share issue ahead of the upcoming scheduled dates. And what is your comment on that? Well, it is an important question. And I thank the person for submitting it. We have consistently communicated, both in our recent quarterly reports and annual reports, that our future capital requirements depend on several factors, including, obviously, our regulatory timelines, the launch timelines, the commercial uptake activities, and the development activities. Our cash position, as stated in the Q2 report, remains unchanged. We will execute and maintain our financial stewardship to balance the necessary development and manufacturing requirements in the short term while maintaining our operational readiness for launch. We have also communicated that additional financing would be required to support our commercialization and launch planning. We continue to monitor this very closely and evaluate different financing alternatives, including the potential of any capital raise. But we are pleased with the strong support that we have received from our major shareholders in previous financing and their ongoing and continuous support to our business and our development pathway. I would like to add that the CRL today, as it relates to financing, does not require a new development program. It means producing, testing, and compiling the quality review additional requirements needed in commercial scale batch data. Since these were already part of our launch preparation, the issue is manageable. Thank you, Jacob. Thank you, Blake. So, a lot of interest and a lot of questions. We have already covered several of them. And I am trying to orient myself around this. We do get questions about whether we anticipate a class one or class two review, meaning the timeline from resubmission to the PDUFA date from the FDA, whether it will be 2 or 6 months. So we have those questions. So would you like to respond to that? So I mean, obviously we are extremely keen to ensure that we have the shortest and the fastest route through to an approval for both Norlevo and Norlevo for Dasani. I do not want to speculate whether it would be a Class 1 or a Class 2 review. Our focus today is making sure that we deliver, analyze, and manufacture these consecutive commercial scale batches. Do that quickly in partnership with the new owners at Venta and Near Pharma, and make sure that we are able to satisfy the additional data that the FDA has requested. Right. There are actually two questions here that I would have thought were covered. But maybe; they are quite important to have clarified. So I think we should go over them again. One is that you said you plan to resubmit the NDA as soon as possible, but can you and will you be able to file it before the status of the Nevada facility and the clearance of the GMP issues have been resolved? Yeah, so maybe we can start by clarifying the answer to that. Can we resubmit, or do we have to wait for the resolution of the GMP issues at the pharma? Or can we resubmit while that is still pending? I think the key point here is that the principal bottleneck remains Near Pharma's regulatory status, and we've communicated that before. And that is not directly within our control. And what we will aggressively manage is the manufacturing of these consecutive commercial batches and the data packages that accompany them. And that is what we are focusing on today. Once that is done, we can resubmit the NDA without waiting for the GMP issues to be resolved. Right. We won't receive an approval until both items are satisfied. But the question is whether we can resubmit the application. The application will require both the approval from the FDA regarding Neopharma, as well as the acceptance of the data that we are providing related to these additional consecutive commercial-scale batches. Yes. Okay. And Hunter Capital asks, are we looking at additional studies? That one is easy to address. I think at this point there is no requirement for additional studies as I mentioned, on the contents of the CRL, or as it relates to the previous CRLs that we've also addressed. So this question for additional studies is actually not something that we are looking at today. Yes, we also have some questions from several angles. Is it necessary or possible to change to a third-party manufacturer? Second source manufacturing has been on our radar. Jacob and team for quite some time. As you know, we had initiated work at a site in 2020. But every capital decision is measured against one question. Does this bring these two assets closer to approval or not? A new facility takes roughly 18 months or more to become operational. Funding that, instead of funding launch readiness, would push out a PDUFA date for both products. It does not advance it, and has consistently sat somewhere between 6 to 12 months ahead of the next regulatory milestone. So we have been prioritizing the approval path appropriately before parallel infrastructure development. That said, we do continuously review our supply chain on all aspects to ensure that we have the right operating model and the right redundancy moving forward. It's not an oversight. Right, I thank everyone for posting so many questions; I struggled a little bit to make sure that nothing slips by. I admit it is a little bit of a struggle to make sure that nothing slips by. But I think we covered the essence of what's been posted in the chat. So I think we can wrap up the Q&A portion. Blake, okay. Thank you. Jacob, thank you, Sophia. I'd like to close by just reiterating the main point here, which is that this CRL does not change our view of danavoreb. About Dasanib or the commercial opportunity. Dasanib is a nearly 2 billion US dollar market today. We are gating items that are in front of us related to Near Pharma's FDA status. The market knew, and we know, that it was time-sensitive. The additional batch data request is manageable documentation. We expect to address this requirement as part of our launch preparation work, which is already underway and will continue into early October. I am pleased to also share with the community that I am planning an investor update presentation at a CML conference, which will be hosted in Gothenburg. The Goldman conference is October 1st, and the dates and details will follow as we confirm them. But in the meantime, I do look forward to your continued support and remain assured that we will continue to advance, both rationally and in parallel, and drive forward to unlock the potential in front of us. Thank you.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…